Clinical Research Directory
Browse clinical research sites, groups, and studies.
Methotrexate Versus Apremilast for Pruritus in Psoriasis
Sponsor: Zarmeen Khawar
Summary
This randomized controlled trial aims to compare the efficacy of Methotrexate versus Apremilast in reducing pruritus and improving quality of life in patients with psoriasis. Eighty patients aged 20 to 60 years with psoriasis involving more than 8% body surface area and associated pruritus will be enrolled and randomly assigned into two groups. Group A will receive oral Apremilast titrated to 30 mg twice daily, while Group B will receive oral Methotrexate 10 mg once weekly for 8 weeks. The primary outcome will be change in Dermatology Life Quality Index (DLQI) score at 8 weeks. Secondary outcomes include change in numerical rating scale for pruritus and assessment of adverse effects. The study will be conducted at Pakistan Emirates Military Hospital Rawalpindi.
Official title: Comparison of Efficacy of Methotrexate Versus Apremilast in the Treatment of Pruritus in Psoriasis: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-02-20
Completion Date
2026-07-20
Last Updated
2026-02-25
Healthy Volunteers
No
Interventions
Apremilast
Oral Apremilast titrated to 30 mg twice daily for 8 weeks.
Methotrexate
Oral Methotrexate 10 mg once weekly for 8 weeks.
Locations (1)
Pak Emirates Military Hospital
Rawalpindi, Punjab Province, Pakistan